A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Recruiting

Phase 3

RemibrutinibA Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Sponsor:

Novartis Pharmaceuticals

Code:

NCT06744920

Conditions

Generalized Myasthenia Gravis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Remibrutinib (Blinded)

Placebo

Remibrutinib (Open Label)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-01. This information was provided to ClinicalTrials.gov by Novartis Pharmaceuticals on 2026-02-20.